The association between plasma carnitines and duration of diabetic ketoacidosis treatment in children with type 1 diabetes

dc.contributor.authorOkdemir, Deniz
dc.contributor.authorAcikgozoglu, Aysel
dc.contributor.authorAkgun, Abdurrahman
dc.contributor.authorEsen, Ihsan
dc.date.accessioned2026-08-12T17:20:32Z
dc.date.issued2022
dc.departmentFırat Üniversitesi
dc.description.abstractObjectives The aim of this study is to determine the plasma free carnitine and acyl-carnitine levels at the time of diabetic ketoacidosis (DKA) diagnosis, and at the end of DKA treatment and to investigate their association with the duration of DKA treatment in children with DKA. Methods A total of 40 children with DKA who were treated consecutively in a tertiary health center for DKA were included in the study. The median age of the children was 11.3 years (1.1-17.5) and 25 of them (62.5%) were girls. In addition to routine blood tests, plasma free carnitine and acyl-carnitine levels were measured just before the start of intravenous insulin therapy and at the time of discontinuation of intravenous insulin therapy when DKA therapy was completed. Results There was no difference in plasma free carnitine and acyl-carnitine levels before and after DKA treatment (p=0.776 and p=0.743 respectively). However, while the frequency of low plasma free carnitine was 30% at the beginning of the treatment, it was observed that this frequency was 20% at the end of the DKA treatment. There was no correlation between duration of DKA treatment and plasma free carnitine or acyl-carnitine levels at admission (p=0.497, r=-0.111 and p=0.474, r=0.116 respectively). Conclusions There is no a relationship between duration of DKA treatment and plasma free carnitine or acyl-carnitine level at admission in children with DKA.
dc.identifier.doi10.1515/jpem-2022-0431
dc.identifier.endpage1508
dc.identifier.issn0334-018X
dc.identifier.issn2191-0251
dc.identifier.issue12
dc.identifier.orcid0000-0003-1700-6778
dc.identifier.pmid36198016
dc.identifier.scopus2-s2.0-85140047791
dc.identifier.scopusqualityQ2
dc.identifier.startpage1505
dc.identifier.urihttps://doi.org/10.1515/jpem-2022-0431
dc.identifier.urihttps://hdl.handle.net/11508/53605
dc.identifier.volume35
dc.identifier.wosWOS:000863929600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWalter de Gruyter Gmbh
dc.relation.ispartofJournal of Pediatric Endocrinology & Metabolism
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectacyl-carnitine
dc.subjectcarnitine
dc.subjectketoacidosis
dc.titleThe association between plasma carnitines and duration of diabetic ketoacidosis treatment in children with type 1 diabetes
dc.typeArticle

Dosyalar